Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sparsentan - Travere Therapeutics

Next Previous
Drug Profile

Sparsentan - Travere Therapeutics

Alternative Names: DARA; FILSPARI; PS-433540; RE-021

Latest Information Update: 31 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer CSL Vifor; Renalys Pharma; Retrophin; Travere Therapeutics
  • Class Anti-inflammatories; Antihypertensives; Isoxazoles; Nerve growth factors; Small molecules; Spiro compounds; Sulfonamides; Urologics; Vascular disorder therapies
  • Mechanism of Action Angiotensin type 2 receptor antagonists; Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy; Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed IgA nephropathy
  • Preregistration Focal segmental glomerulosclerosis
  • Phase II Anti-neutrophil cytoplasmic antibody-associated vasculitis; Hereditary nephritis; Vasculitis
  • Discontinued Hypertension

Most Recent Events

  • 17 Oct 2025 Latest efficacy data from a phase III DUPLEX trial in Focal segmental glomerulosclerosis released by Travere Therapeutics
  • 17 Oct 2025 Pharmaceuticals and Medical Devices Agency approves development plans for Phase III trials of Sparsentan in Glomerulosclerosis and the other in Alport syndrome
  • 10 Sep 2025 The US FDA informed Travere Therapeutics that an advisory committee is no longer needed for Focal segmental glomerulosclerosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top